Flow Traders U.S. LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 71.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 4,456 shares of the company’s stock after selling 10,960 shares during the period. Flow Traders U.S. LLC’s holdings in Novo Nordisk A/S were worth $239,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Aevitas Wealth Management Inc. bought a new stake in Novo Nordisk A/S in the fourth quarter valued at $107,000. Zions Bancorporation raised its position in Novo Nordisk A/S by 677.1% in the 3rd quarter. Zions Bancorporation now owns 2,852 shares of the company’s stock worth $137,000 after buying an additional 2,485 shares during the last quarter. SeaCrest Wealth Management LLC purchased a new position in Novo Nordisk A/S in the 4th quarter worth about $176,000. Addenda Capital Inc. purchased a new position in Novo Nordisk A/S in the 4th quarter worth about $201,000. Finally, Charter Trust Co. purchased a new position in Novo Nordisk A/S in the 4th quarter worth about $201,000. Hedge funds and other institutional investors own 6.71% of the company’s stock.
Novo Nordisk A/S (NYSE NVO) traded down $0.04 on Wednesday, hitting $50.29. The stock had a trading volume of 923,215 shares, compared to its average volume of 1,573,148. Novo Nordisk A/S has a fifty-two week low of $33.10 and a fifty-two week high of $58.37. The company has a market cap of $98,140.00, a P/E ratio of 19.64, a price-to-earnings-growth ratio of 3.32 and a beta of 0.63.
Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.53 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.04). Novo Nordisk A/S had a net margin of 34.09% and a return on equity of 82.72%. The company had revenue of $4.43 billion for the quarter, compared to the consensus estimate of $4.27 billion. equities analysts anticipate that Novo Nordisk A/S will post 2.63 earnings per share for the current fiscal year.
The company also recently disclosed a special dividend, which will be paid on Tuesday, April 3rd. Stockholders of record on Monday, March 26th will be paid a $0.8117 dividend. This represents a dividend yield of 0.96%. The ex-dividend date of this dividend is Friday, March 23rd. Novo Nordisk A/S’s payout ratio is 32.03%.
Novo Nordisk A/S declared that its Board of Directors has authorized a stock repurchase plan on Thursday, February 1st that authorizes the company to buyback shares. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its shares are undervalued.
NVO has been the subject of a number of recent research reports. Morgan Stanley upgraded Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research note on Friday, December 1st. Deutsche Bank restated a “buy” rating on shares of Novo Nordisk A/S in a research note on Monday, January 8th. Zacks Investment Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $64.00 price objective for the company in a research note on Friday, January 26th. JPMorgan Chase & Co. upgraded Novo Nordisk A/S from an “underweight” rating to a “neutral” rating in a research note on Friday, December 29th. Finally, Bank of America upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, December 6th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $64.00.
Novo Nordisk A/S Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.